Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database
Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns
Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis
